Clark Capital Management Group Inc. cut its holdings in Eli Lilly And Co (NYSE:LLY) by 32.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,823 shares of the company’s stock after selling 1,357 shares during the period. Clark Capital Management Group Inc.’s holdings in Eli Lilly And Co were worth $366,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. BDO Wealth Advisors LLC lifted its position in shares of Eli Lilly And Co by 29.4% during the 4th quarter. BDO Wealth Advisors LLC now owns 2,229 shares of the company’s stock worth $258,000 after buying an additional 506 shares in the last quarter. Janney Capital Management LLC bought a new stake in shares of Eli Lilly And Co in the 1st quarter worth approximately $246,000. Thoroughbred Financial Services LLC raised its holdings in shares of Eli Lilly And Co by 1.4% in the 1st quarter. Thoroughbred Financial Services LLC now owns 7,612 shares of the company’s stock worth $988,000 after purchasing an additional 105 shares during the period. Smithfield Trust Co. raised its holdings in shares of Eli Lilly And Co by 1.6% in the 1st quarter. Smithfield Trust Co. now owns 7,277 shares of the company’s stock worth $944,000 after purchasing an additional 114 shares during the period. Finally, FDx Advisors Inc. raised its holdings in shares of Eli Lilly And Co by 48.3% in the 4th quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock worth $2,257,000 after purchasing an additional 6,356 shares during the period. Institutional investors own 79.38% of the company’s stock.
A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. TheStreet cut shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a report on Thursday, May 9th. BMO Capital Markets lowered their price target on shares of Eli Lilly And Co to $130.00 and set an “outperform” rating on the stock in a report on Monday, April 22nd. Barclays reaffirmed a “buy” rating and issued a $140.00 price target on shares of Eli Lilly And Co in a report on Sunday, April 14th. Finally, Goldman Sachs Group started coverage on shares of Eli Lilly And Co in a report on Tuesday, May 28th. They set a “buy” rating and a $135.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $119.99.
Shares of LLY traded down $4.02 during mid-day trading on Wednesday, reaching $111.34. 4,532,860 shares of the stock traded hands, compared to its average volume of 10,891,441. The business has a fifty day simple moving average of $115.71. The firm has a market cap of $111.99 billion, a P/E ratio of 20.06, a price-to-earnings-growth ratio of 2.05 and a beta of 0.27. The company has a current ratio of 1.12, a quick ratio of 0.85 and a debt-to-equity ratio of 5.50. Eli Lilly And Co has a 1 year low of $84.64 and a 1 year high of $132.13.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating analysts’ consensus estimates of $1.32 by $0.01. The firm had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.31 EPS. Equities analysts anticipate that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $0.645 dividend. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 annualized dividend and a yield of 2.32%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.
In other Eli Lilly And Co news, VP Michael J. Harrington sold 16,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the sale, the vice president now directly owns 110,300 shares in the company, valued at $12,874,216. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Aarti S. Shah sold 1,800 shares of the company’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $125.85, for a total transaction of $226,530.00. Following the sale, the senior vice president now owns 18,425 shares of the company’s stock, valued at $2,318,786.25. The disclosure for this sale can be found here. Insiders sold 40,112 shares of company stock valued at $4,820,705 over the last quarter. 0.11% of the stock is owned by company insiders.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: How is an ETF different from a mutual fund?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.